Osimertinib Plus Antiangiogenic Agents: A Promising New Paradigm With Uncertain Results

Shaohui Wang¹, Yinan Yao¹, Wenjing Wang¹+4

• ¹Shaohui Wang, MD, State Key Laboratory of Southwestern Chinese Medicine Resources, School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China, Yinan Yao, MD, Department of Respiratory and Critical Care Medicine of The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, Zhejiang, China, Wenjing Wang, MM, Lisha Ye, MM and Huihui Li, MM, Postgraduate Training Base Alliance, Wenzhou Medical University, Wenzhou, Zhejiang, China, Qinglin Li, MD, Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China, Xiaoling Xu, MD, Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.